DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
NYSE:DBD - New York Stock Exchange, Inc. - US2536512021 - Common Stock - Currency: USD
DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 32 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
In the past year DBD had a positive cash flow from operations.
In the past 5 years DBD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
DBD has a Return On Assets of -0.47%. This is comparable to the rest of the industry: DBD outperforms 53.13% of its industry peers.
DBD has a better Return On Equity (-1.77%) than 65.63% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.96%, DBD is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 15.57%.
The last Return On Invested Capital (9.96%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.47% | ||
| ROE | -1.77% | ||
| ROIC | 9.96% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
The Operating Margin of DBD (7.66%) is better than 65.63% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
DBD's Gross Margin of 25.27% is in line compared to the rest of the industry. DBD outperforms 43.75% of its industry peers.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.66% | ||
| PM (TTM) | N/A | ||
| GM | 25.27% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DBD is creating some value.
The number of shares outstanding for DBD remains at a similar level compared to 1 year ago.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
Compared to 1 year ago, DBD has an improved debt to assets ratio.
2.2 Solvency
DBD has an Altman-Z score of 1.84. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
DBD has a Altman-Z score of 1.84. This is comparable to the rest of the industry: DBD outperforms 56.25% of its industry peers.
The Debt to FCF ratio of DBD is 7.19, which is on the high side as it means it would take DBD, 7.19 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.19, DBD is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
DBD has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
DBD's Debt to Equity ratio of 1.01 is on the low side compared to the rest of the industry. DBD is outperformed by 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 7.19 | ||
| Altman-Z | 1.84 |
ROIC/WACC1.04
WACC9.6%
2.3 Liquidity
DBD has a Current Ratio of 1.32. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.32, DBD is doing worse than 62.50% of the companies in the same industry.
A Quick Ratio of 0.90 indicates that DBD may have some problems paying its short term obligations.
DBD has a Quick ratio (0.90) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 997.67% over the past year.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
The Revenue has decreased by -0.25% in the past year.
DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.18% yearly.
EPS 1Y (TTM)997.67%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-67.88%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-4.74%
3.2 Future
Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.37% on average per year.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.37% yearly.
EPS Next Y0.69%
EPS Next 2Y10.07%
EPS Next 3Y9.37%
EPS Next 5YN/A
Revenue Next Year0.71%
Revenue Next 2Y1.3%
Revenue Next 3Y2.37%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.43, which indicates a very decent valuation of DBD.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than 75.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.98. DBD is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 11.35, the valuation of DBD can be described as very reasonable.
DBD's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of DBD to the average of the S&P500 Index (21.38), we can say DBD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.43 | ||
| Fwd PE | 11.35 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 93.75% of the companies in the same industry.
87.50% of the companies in the same industry are more expensive than DBD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.6 | ||
| EV/EBITDA | 5.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)16.45
PEG (5Y)N/A
EPS Next 2Y10.07%
EPS Next 3Y9.37%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
44.12
+0.12 (+0.27%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.7%
Inst Owner Change0.35%
Ins Owners1.65%
Ins Owner Change2.88%
Market Cap1.66B
Analysts83.33
Price Target73.78 (67.23%)
Short Float %2.49%
Short Ratio6.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.55%
Min EPS beat(2)-52.17%
Max EPS beat(2)-8.92%
EPS beat(4)2
Avg EPS beat(4)88.8%
Min EPS beat(4)-52.17%
Max EPS beat(4)407.85%
EPS beat(8)4
Avg EPS beat(8)-134.96%
EPS beat(12)6
Avg EPS beat(12)-116.3%
EPS beat(16)7
Avg EPS beat(16)-96.43%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.88%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-1.24%
Max Revenue beat(4)1.85%
Revenue beat(8)3
Avg Revenue beat(8)-0.76%
Revenue beat(12)3
Avg Revenue beat(12)-2.43%
Revenue beat(16)3
Avg Revenue beat(16)-2.66%
PT rev (1m)3.33%
PT rev (3m)15.73%
EPS NQ rev (1m)-5.88%
EPS NQ rev (3m)-54.08%
EPS NY rev (1m)-4.33%
EPS NY rev (3m)-22%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-6.34%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.43 | ||
| Fwd PE | 11.35 | ||
| P/S | 0.44 | ||
| P/FCF | 12.6 | ||
| P/OCF | 11.13 | ||
| P/B | 1.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.42 |
EPS(TTM)3.86
EY8.75%
EPS(NY)3.89
Fwd EY8.81%
FCF(TTM)3.5
FCFY7.94%
OCF(TTM)3.96
OCFY8.99%
SpS99.68
BVpS24.71
TBVpS-11.57
PEG (NY)16.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.47% | ||
| ROE | -1.77% | ||
| ROCE | 12.61% | ||
| ROIC | 9.96% | ||
| ROICexc | 11.55% | ||
| ROICexgc | 37.87% | ||
| OM | 7.66% | ||
| PM (TTM) | N/A | ||
| GM | 25.27% | ||
| FCFM | 3.51% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexcg growth 3Y-11.73%
ROICexcg growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score5
Asset Turnover1.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 7.19 | ||
| Debt/EBITDA | 2.25 | ||
| Cap/Depr | 13.15% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 35.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.9 | ||
| Altman-Z | 1.84 |
F-Score5
WACC9.6%
ROIC/WACC1.04
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)997.67%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-67.88%
EPS Next Y0.69%
EPS Next 2Y10.07%
EPS Next 3Y9.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-4.74%
Revenue Next Year0.71%
Revenue Next 2Y1.3%
Revenue Next 3Y2.37%
Revenue Next 5YN/A
EBIT growth 1Y89.95%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year23.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y147.22%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y158.69%
OCF growth 3Y6.68%
OCF growth 5Y26.59%